Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy by Matusali, G et al.
Detection of Simian Immunodeficiency Virus in Semen,
Urethra, and Male Reproductive Organs during Efficient
Highly Active Antiretroviral Therapy
G Matusali, N Dereuddre Bosquet, A Le Tortorec, M Moreau, A-P Satie, D
Mahe´, P Roumaud, O Bourry, N Sylla, S Bernard-Stoecklin, et al.
To cite this version:
G Matusali, N Dereuddre Bosquet, A Le Tortorec, M Moreau, A-P Satie, et al.. Detection
of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during
Efficient Highly Active Antiretroviral Therapy. Journal of Virology, American Society for
Microbiology, 2015, 89 (11), pp.5772-5787. <10.1128/JVI.03628-14 >. <hal-01139816>
HAL Id: hal-01139816
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01139816
Submitted on 6 Nov 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Detection of Simian Immunodeficiency Virus in Semen, Urethra, and
Male Reproductive Organs during Efficient Highly Active
Antiretroviral Therapy
G. Matusali,a N. Dereuddre-Bosquet,b,d,e A. Le Tortorec,a M. Moreau,a A.-P. Satie,a D. Mahé,a P. Roumaud,a O. Bourry,a N. Sylla,b,d,e
S. Bernard-Stoecklin,b,d,e A. Pruvost,c R. Le Grand,b,d,e N. Dejucq-Rainsforda
Inserm U 1085-IRSET, Université de Rennes 1, Structure Fédérative Recherche Biosit, Campus de Beaulieu, Rennes, Francea; CEA, DSV/iMETI, Division of Immuno-Virology,
IDMIT, Fontenay-aux-Roses, Franceb; CEA, Department of Pharmacology and Immunoanalyses, DSV/iBiTec-S, Gif sur Yvette, Francec; Université Paris-Sud, UMR1184,
Fontenay-aux-Roses, Franced; Inserm, U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Fontenay-aux-Roses, Francee
ABSTRACT
A number of men receiving prolonged suppressive highly active antiretroviral therapy (HAART) still shed human immunodefi-
ciency virus (HIV) in semen. To investigate whether this seminal shedding may be due to poor drug penetration and/or viral
production by long-lived cells within male genital tissues, we analyzed semen and reproductive tissues frommacaques chroni-
cally infected with simian immunodeficiency virus mac251 (SIVmac251) who were treated for 4 months with HAART, which was
intensified over the last 7 weeks with an integrase inhibitor. We showed that a subset of treated animals continued shedding SIV
in semen despite efficient HAART. This shedding was not associated with low antiretroviral drug concentrations in semen or in
testis, epididymis, seminal vesicles, and prostate. HAART had no significant impact on SIV RNA in the urethra, whereas it drasti-
cally reduced SIV RNA levels in the prostate and vas deferens and to a lesser extent in the epididymis and seminal vesicle. The
only detectable SIV RNA-positive cells within the male genital tract after HAART were urethral macrophages. SIV DNA levels in
genital tissues were not decreased by HAART, suggesting the presence throughout the male genital tract of nonproductively in-
fected cells. In conclusion, our results demonstrate that 4 months of HAART induced variable and limited control of viral infec-
tion in the male reproductive organs, particularly in the urethra, and suggest that infected long-lived cells in the male genital
tract may be involved in persistent seminal shedding during HAART. These results pave the way for further investigations of
male genital organ infection in long-term-treated infected individuals.
IMPORTANCE
A substantial subset of men receiving prolonged HAART suppressing viral loads in the blood still harbor HIV in semen, and
cases of sexual transmission have been reported. To understand the origin of this persistence, we analyzed the semen andmale
reproductive tissues from SIV-infected macaques treated with HAART.We demonstrated that persistent seminal shedding was
not linked to poor drug penetration in semen or semen-producing prostate, seminal vesicle, epididymis, and testis. We revealed
that HAART decreased SIV RNA to various extents in all male genital organs, with the exception of the urethra, in which SIV
RNAmacrophages were observed despite HAART. Importantly, HAART did not impact SIV DNA levels in the male genital or-
gans. These results suggest that infection of male genital organs, and particularly the urethra, could be involved in the release of
virus in semen during HAART.
Approximately 35.3 million people worldwide are living withhuman immunodeficiency virus (HIV)/AIDS, and 2.3 mil-
lion new infections occur annually (1). Over 80% of these new
infections are caused by unprotected sexual intercourse. The risk
of sexual transmission of HIV is strongly correlated with HIV
RNA levels in genital secretions (2). Because semen is the most
common vector of HIV dissemination worldwide (3–5), prevent-
ing HIV transmission by semen is a public health priority. Highly
active antiretroviral (ARV) therapy (HAART), although not erad-
icating the virus, does greatly and rapidly reduce blood and genital
secretion viral loads (usually within 1 month) in a majority of
patients, leading to undetectable levels in standard assays (6–8).
However, a subset of individuals receiving HAART continue to
have detectable virions and infected cells in their semen for
months to years after therapy initiation. This persistent virus re-
lease in semen occurs despite an undetectable blood HIV RNA
load and an absence of detectable sexually transmitted infections
(STIs), the latter being a well-identified factor favoring HIV shed-
ding in semen irrespective of HAART (9–11). HIV RNA has been
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evidenced in the semen of 3% to 48% of chronically infected men
under suppressive HAART for over 6 months with no detected
STIs (6, 12–19) (see additional references in reference 20). Levels
of HIV RNA detected during HAART are often low; nevertheless,
high levels of shedding (i.e., 1,000 RNA copies/ml) have been
described in a substantial subset of individuals (6, 14, 15, 17–19).
This level has been associated with heterosexual transmission
events (2) and increased risk of HIV transmission in vitro (21).
Furthermore, rectal transmission in macaques has been shown to
occur with a virus level much lower than that needed for vaginal
transmission (22), suggesting that even low levels ofHIV in semen
may lead to transmission through the rectum. In addition to viral
RNA (vRNA) in the cell-free fraction of semen, infected leuko-
cytes harboring HIV DNA and capable of productive infection
have been detected in the semen of men receiving HAART (7,
23–26). Recent evidence indicates that HIV-infected cells in gen-
ital secretions could play a role in the sexual transmission of HIV
(27–29). Although HAART in the infected partner very signifi-
cantly reduces heterosexual transmission at the population level, a
risk for residual transmission remains (30–32). Importantly, the
transmission probabilities are higher in men having sex with men
(MSM) than in heterosexual couples (33, 34). The risk of HIV
transmission in MSM despite HAART in the infected partner has
never been assessed in large cohorts and is currently under study
(35). As a matter of fact, cases of sexual transmission from men
under suppressive HAART have been reported (36, 37), and a
resurgence of the HIV-1 epidemic among MSM is occurring in
countries where potent HAART is available (38).
In this context, understanding the origins of persistent HIV
shedding in semen despite efficient HAART is of prime impor-
tance. Sequences derived from HIV RNA recovered from the se-
men of men under suppressive HAART were found to be distinct
from those from blood (6). This is similar to the compartmental-
ization of viral strains between blood and semen described in a
subset of therapy-naive men (39–41) and macaques (42). Such a
compartmentalization indicates that HIV/simian immunodefi-
ciency virus (SIV) contaminating the semen of those individuals
arises from the production of viral strains within the male genital
tract (MGT) with distinct evolution from blood strains. We and
others have revealed that macrophages and CD4 T cells present
in semen-producing organs (testis, epididymis, prostate, seminal
vesicle) of therapy-naive men and macaques during the chronic
stage are infected by HIV/SIV and may efficiently seed the semen
with free viral particles and infected cells (43, 45–48, 100). There-
fore, viral persistence in the semen may be attributable to viral
production within the MGT organs, either because of incomplete
penetration of antiretroviral drugs and/or because of the infection
of long-lived cells in those tissues. Because of the great difficulty in
accessing MGT organs frommen shedding HIV in semen despite
HAART, this hypothesis has never been explored. Our study is the
first to analyze both semen and MGT tissue infection during
HAART, taking advantage of the SIVmac251-infected cynomol-
gus macaques. This animal model not only offers the unique op-
portunity to access semen and MGT organs but also to control
drug intakes and tissue distribution. Importantly we and others
recently validated its relevance to HIV pathogenesis in the male
genital tract (29, 42, 45).
We focused on the measurement of viral loads and drug con-
centrations in semen andMGT organs after 4 months of standard
HAART intensified over the last 7 weeks with raltegravir, as well as
on the characterization of SIV target and infected cells in selected
MGT organs from untreated and HAART-treated animals. We
showedpersistent shedding of SIVRNA in the semenof a subset of
animals, despite HAART efficiency in blood. The persistent shed-
ding in semen did not correlate to drug concentrations in semen
and testis, epididymis, seminal vesicle, and prostate. Using quan-
titative reverse transcription (RT)-PCR and in situ hybridization
combined with immunofluorescence, we found that HAART de-
creased SIV RNA levels to various extents in all MGT organs with
the exception of the urethra. The urethra was the onlyMGTorgan
encompassing SIV RNA cells after HAART, which we identified
to be macrophages. We also discovered that SIV DNA levels in
MGT organs are not affected by HAART. Our results suggest that
long-lived infected cells in MGT organs, in particular the urethra,
could be involved in persistent viral shedding during HAART.
MATERIALS AND METHODS
Ethics statement. Adult cynomolgus macaques (Macaca fascicularis) im-
ported fromMauritius were housed in the facilities of the Commissariat à
l’Energie Atomique et aux Energies Alternatives (CEA; Fontenay-aux-
Roses, France). Nonhuman primates (NHP) are used at the CEA in ac-
cordance with French national regulation and under national veterinary
inspectors (CEA permit number A 92-032-02). The CEA is in compliance
with the Public Health Service Policy on Humane Care and Use of Labo-
ratory Animals of the Office for Laboratory Animal Welfare (OLAW;
United States) (49) underOLAWassurance numberA5826-01. The use of
NHP at CEA is in accordance with the recommendation of the newly
published European directive (2010/63, recommendationNu9) (50). An-
imals were housed in adjoining individual cages allowing social interac-
tions, under controlled conditions of humidity, temperature, and light
(12-hour light/12-hour dark cycles). Water was available ad libitum. An-
imals weremonitored and fed 1 or 2 times daily with commercial monkey
chow and fruits by trained personnel. Macaques were provided with en-
vironmental enrichment, including toys, novel foodstuffs, and music un-
der the supervision of the CEA Animal Welfare Body. The protocols em-
ployed were approved under statement number 10-060 (13 November
2012) by the ethical committee of the CEA Comité d’Ethique en Expéri-
mentation Animale, registered with the French Research Ministry under
number 44. The animals were used under the supervision of the veteri-
narians in charge of the animal facility. Experimental procedures were
conducted after animal sedation with ketamine chlorhydrate (Rhone-
Merieux, Lyon, France; 10 mg/kg of body weight) as previously described
(51). Tissues from theMGTwere collected during animal necropsy at the
end of the treatment after sedation of animals (ketamine chlorhydrate, 10
mk/kg) followed by euthanasia (sodium pentobarbital, 180 mg/kg).
Animals, infection, and treatment. Fourteen adult male cynomolgus
macaques (3 to 4 years old, body weight of 5 kg, all mature as attested
by the presence of full spermatogenesis) were intravenously inoculated
with 5,000 50% animal infectious doses (AID50) of pathogenic cell-free
SIVmac251 as previously described (51). Six macaques (OKU6, OBCY5,
OBRG6, OBCA5, 30235, and 23014) were given two reverse-transcriptase
inhibitors, (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA; i.e.,
tenofovir [TFV]; 20 mg/kg) and emtricitabine (FTC; 50 mg/kg), once a
day subcutaneously, as well as the protease inhibitor lopinavir (LPV; 36
mg/kg) boosted with ritonavir (RTV; 12 mg/kg) orally. This treatment
was initiated 47 weeks postinoculation, administered for 17 weeks, and
intensified during the last 7 weeks with an integrase inhibitor, raltegravir
(RAL; 200 mg/animal) orally. The others eight macaques (20351, 30675,
19554, 30855, 30569, 29965, 30717, and 30838) were untreated.
Specimen collections and blood and seminal viral load measure-
ment. Blood and semen were periodically collected throughout the infec-
tion, and at the time of euthanasia, blood plasma viral loads (PVL) and
semen viral loads (SVL) were assessed as previously described (29). The
detection limit was estimated at 12 copies/ml in both blood and semen
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samples. Tissues (testes, epididymides, vas deferens, seminal vesicles,
prostate, penile urethra, lymph nodes, and spleen) were collected imme-
diately after euthanasia and exsanguination of the animals, extensively
washed, and cut into fragments weighing about 300 mg each. The frag-
ments were either stored at80°C or fixed in 4% formaldehyde.
Protocol for SIVDNAandRNAquantification in tissues.TotalDNA
and RNA were extracted from frozen tissues using the QIAamp DNA
tissue minikit and the RNeasy isolation kit (both Qiagen), respectively.
Tissue DNA and cDNA fromMGT organs and spleen were subjected to a
preamplification step followed by a quantitative real-time (TaqMan) PCR
step, as previously described (52, 53), with the followingmodifications. The
two primer sets for gag and actin were the same for the preamplification
and real-time PCR steps (SIVgag-F, GCCAGGATTTCAGGCACTGT;
SIVgag-R, GCTTGATGGTCTCCCACACAA; Act-F, TACAGCTTCACC
ACCACGG; Act-R, TGCTCGAAGTCTAGGGCGA). The preamplifi-
cation PCR mixture contained both pairs of primers (multiplex PCR),
and the reaction mixture consisted of 5 M deoxynucleoside triphos-
phates (dNTPs), 1 U of Taq polymerase, 10 l of Qiagen 10 buffer, and
25 nM each primer in a total volume of 100 l. The PCR settings were
94°C for 3 min, followed by 20 cycles of 94°C for 45 s, 56°C for 2 min, and
72°C for 1 min 30 s. A total of 10 l of the product of the first PCR was
subsequently used as a template in the second real-time PCR amplifica-
tion, performed on ABI 7500 using commercially available master mix,
500 nM the specific primers indicated above, and 200 nM target probe,
MGB (AAGGTTGCACCCCCTATGACATTAATCAGATGTTA [SIVgag])
or 6-carboxytetramethylrhodamine (TAMRA; AATCGTGCGTGACATTA
AGGAGAAGCTGTG [actin]). For RNA quantitation, the eluted RNA
samples were first subjected to DNase treatment (Promega) to remove
contaminating DNA and subsequently submitted to reverse transcriptase
reactions using the high-capacity RNA-to-cDNA kit (Applied Biosys-
tems), according to the manufacturer’s instructions.
The protocol for real-time PCR quantification and the preamplifica-
tion step was validated as follows. Standard curves for SIVgag and actin
copy numbers were built with serial dilutions of a pCRII-TOPO plasmid
DNA (Invitrogen) in which the SIVgag and the actin regions of interest
were inserted (45). The same efficiency of amplification and a linear dy-
namic range of 10 to 1010 copies were observed for the two regions of
interest (see Fig. S1A in the supplementalmaterial). SIVgag and actin copy
numbers in unknown samples were systematically inferred by plotting the
threshold cycle (CT) value against this calibration curve (see Fig. S1A).
The amount of input DNA or cDNAwas normalized through actin quan-
tification for each PCR.We assessed that the preamplification efficiencies
for SIVgag and cellular actin were nearly identical, by comparing the
slopes of the CT values to cycles of preamplification curves (10, 15, 20,
and 25 cycles of preamplification tested), the CT (CT  CTSIVgag 
CTactin), and the CT values (CT CTxcycles CT0cycle) (see
Fig. S1B). The efficiencies between two targets are considered equal when
the CT is in the range between 1.5 and 1.5 (61); the CT values
obtained with our samples were all in this validating range. The pream-
plification factor was determined by quantifying actin and gag by real-
time PCR performed before and after the preamplification step. The same
preamplification factor was observed for the two targets.
We chose to run 20 cycles of preamplification in order to enhance the
possibility of detecting SIV infection in low-infected samples from treated
animals, without affecting the efficiency of the real-time PCR step with a
too high input of template. We assessed that no PCR inhibition occurred
with the amount of template input by comparing the results for actin and
SIVgag for a range of preamplification cycles (see Fig. S1B) and of tem-
plate dilutions (see Fig. S1C). For actin quantification, the first PCR prod-
uct was diluted 1/1,000 to obtain CT in the middle of the curve (see Fig.
S1C). The reproducibility of the 2-step protocol was assessed by perform-
ing 4 preamplifications followed by quantitative PCR on DNA and RNA
(see Fig. S1D). To increase the chances of detection of focal infection of
the testis, epididymis, prostate, and seminal vesicle, as we and others have
previously described (45, 52, 54), two independent fragments of each
tissue were assayed in 4 preamplification PCRs, each performed on 500 ng
of extracted DNA or on 200 ng of reverse-transcribed RNA. Regarding
penile urethra, one fragmentwas tested, as only a limited quantity of tissue
was available because of the small size of this duct inmacaques. The lack of
contamination in PCR assays was systematically ensured by concurrently
running a minimum of 4 negative controls. For all assays, no positive
signals were detected in the negative controls or in the non-reverse-tran-
scribed (–RT) controls for RNA assays. Quantification of SIV DNA in
lymph nodes was performed as previously described (55). Results were
expressed as SIVgag copy numbers per copy of actin for both vRNA and
viral DNA (vDNA). The presence of a mix of haploid and diploid cells in
the testis and epididymis prevented extrapolation of actin copy number to
cell number for vDNA quantification. We validated actin as a reference
gene for RNAquantification amongMGTorgans (see Fig. S1E) as follows.
Equivalent volumes of reverse-transcribed product corresponding to 5 ng
equivalent RNA extracted from MGT organs from 3 to 15 animals were
subjected to real-time PCR amplification performed in a 25-l total vol-
ume as described above. The PCR settings were 95°C for 10min, followed
by 40 cycles of 95°C for 15 s and 60°C for 1 min. The specific primers and
TAMRA probes for actin were as described above. Those for glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) and peptidylpropyl isomer-
ase A (PPIA) were as previously described (56). The relative expression of
each mRNA was calculated by the 2CT method (61), where CT is
obtained for each sample by subtracting theCT value for each gene from a
reference geneCT value, and theCT is obtained by subtraction of the
Ct from one sample from the Ct of a reference sample. The prostate
from one macaque was used for all assays as the reference CT.
SIVDNAdetection in semen.Quantification of DNA in semen (sem-
inal cell fraction) performed as described above was not possible due to
the too low DNA quantity rescued from the cell pellet tested. DNA ex-
tracted from the seminal cell pellet was thus subjected to a qualitative
nested PCR amplifying SIVmac251 env, with primer pairs previously de-
scribed by and conditions adapted from Keele et al. (57). Briefly the first
round of PCR was performed on 30 ng of template in 25 l of PCR mix
containing 0.2 mM deoxynucleoside triphosphates (Promega), 1 U of
Phusion Taq (New England Biolabs), and 300 nM each primer in 1
Phusion Taq buffer (New England Biolabs). The PCR settings were as
follows: 98°C for 45 s, followed by 35 cycles of 98°C for 15 s, 55°C for 30 s,
and 72°C for 6 min. A total of 1 l of the product of the first PCR was
subsequently used as a template in the secondnested PCRperformed in 25
l of PCRmix as described above and with the same PCR settings but for
40 cycles. The product of the second PCR was then run on a 1.2% agarose
gel and analyzed.
ISH for SIV RNA and phenotyping of infected cells. Formalin-fixed,
paraffin-embedded tissues were assayed for SIV RNA expression using a
digoxigenin-labeling technique (58, 59) modified as we previously de-
scribed (54). The digoxigenin-UTP-labeled riboprobe thatwas used spans
the whole genome of SIVmac239 (Lofstrand Labs, Gaithersburg, MD,
USA). Nitroblue tetrazolium-5-bromo-4-chloro-3-indolyl phosphate
toluidinium (NBT-BCIP) was used to visualize infected cells in the tissues
of treated and untreated animals. The specificity of the hybridization sig-
nal was systematically checked by hybridizing sense probes with parallel
sections and antisense probes on uninfected genital tissues. Positive con-
trols (MGT tissue from a highly infected macaque and lymphoid tissue
from an untreated animal) were run concomitantly. In situ hybridization
(ISH)-stained tissues were visualized and photographedwith anOlympus
Proxis microscope and a Zeiss AxioCam ICc1 camera. A minimum of 30
sections/organ/animal were analyzed.
Characterization of infected cells in genital tissues was performed us-
ing ISH combined with immunostaining for cell markers, as described
before (54, 59). Briefly, sections were treated with methanol-hydrogen
peroxide, and the hybridized tissues were incubated with sheep anti-
digoxigenin peroxidase (SAD-POD;RocheMolecular Biochemicals) for 1
h at room temperature. SAD-PODwas detected by a fluorescent tyramide
signal amplification (TSA) technique (TSA plus fluorescein isothiocya-
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nate [FITC], NEL741; PerkinElmer). Following ISH assay, the sections
were incubated with a combination of twomouse monoclonal antibodies
against CD68 (clone KP1, 4 g/ml; Dako) and CD163 (clone 10D6, 0.5
g/ml; Novocastra) and with a monoclonal rabbit anti-human CD3
antibody (SP7, 1:100; Thermo Scientific). Sections were subsequently
stained with a goat Alexa-594 anti-mouse IgG antibody (4 g/ml; Invit-
rogen BP) and a goat Alexa-633 anti-rabbit IgG antibody (4g/ml; Invit-
rogen BP). Positive (MGT tissue from a highly infected animal) and neg-
ative (hybridization with a sense probe on parallel sections of infected
animals and hybridization with an antisense probe on MGT tissue from
an uninfected animal) controls were systematically run. Additional con-
trols for TSA amplification included mock hybridization (no probe) and
hybridization in the absence of primary antibodies. The double-stained
sections were mounted in Vectashield mounting medium with DAPI
(4=,6-diamidino-2-phenylindole; Vectashield, Vector Laboratories, Ltd.).
Images were acquired with a Zeiss AxioImager M1 microscope equipped
with 4 filters and analyzed with AxioVision Rel 4.7.1 and ImageJ software.
The final images were generatedwith Adobe PhotoshopCS2. Aminimum
of 30 sections/organ/animal were analyzed.
Immunohistochemistry. The following antibodies andmatching iso-
type controls were used at the indicated concentrations: mousemonoclo-
nal anti-HLA-DR (clone TAL.1B5, 0.6 g/ml; Dako), anti-CD68 (clone
KP1, 4 g/ml; Dako), anti-CD163 (clone10D6, 0.5 g/ml; Novocastra),
anti-CD4 (clone 1F6, 2.5 g/ml; Novocastra), anti-TIA-1 (clone 2G9, 1
g/ml; Immunotech), anti-MAC387 (1.42 g/ml; Dako), anti-DC-SIGN
(2 g/ml; R&D Systems), anti-CD20 (clone F7.238, 0.44 g/ml; Dako),
rabbit monoclonal anti-CD3 (SP7, 1:100; Thermo Scientific), mouse
IgG1 isotype control (Dako), and rabbit IgG isotype control (Jackson
ImmunoResearch). Alexa-633, Alexa-594, or biotin-conjugated second-
ary antibodies were purchased from Invitrogen andDako. Immunohisto-
chemistry was performed as previously described (43). No staining was
ever observed with isotype control antibodies. For quantitative and semi-
quantitative measurement, slides were scanned with Nanozoomer NDP
(Hamamatsu), and cell counts were performed using the ImageJ software.
For semiquantitative analysis of HLA-DR cell foci, 8 untreated and 6
treated animals were included and 4 sections/organ/animal were
screened. For quantitative analysis of T lymphocytes and macrophages,
counting was undertaken on 3 animals/group, and 2 sections/organ/ani-
mal were screened.
Determination of antiretroviral drug concentrations in blood, se-
men, and tissues. TFV, FTC, LPV, RTV, and RAL were quantified in the
treated macaques’ seminal fluids. TFV-diphosphate (TFV-DP) and FTC-
triphosphate (FTC-TP), the intracellular active metabolites of TFV and
FTC, respectively, and LPV, RTV, and RAL concentrations were deter-
mined in the testis, the epididymis, the prostate, and the seminal vesicles.
All analyses were performed using 2-chloroadenosine and 2-chloroad-
enosine-5=triphosphate, LPV D8, RTV D6, and RAL D4 as internal stan-
dards. A simple protein precipitationwas used for seminal fluid and blood
plasma sample preparation. Tissue samples were homogenized using a
Precellys tissue homogenizer (Bertin Technologies). TFV, FTC, TFV-DP,
FTC-TP, LPV, RTV, and RAL from extract samples were quantified using
a Waters Acquity ultraperformance liquid chromatography (UPLC) sys-
tem with a 2.1- by 100-mm, 1.7-m Acquity UPLC BEH RP18 shield
column coupled to aWaters Xevo TQ-MSmass spectrometer operated in
positive ion electrospray multiple-reaction-monitoring (MRM) mode.
Two chromatographic conditions were used, one for FTC and TFV and
another one for RTV, LPV, RAL, TFV-DP, and FTC-TP, both adapted
from previously published methods (105, 106).
Data analysis. All data visualization and statistical analyses were car-
ried out with GraphPad Prism 5.03 software (GraphPad Software, La
Jolla, CA, USA). Nonparametric Spearman’s rank correlation tests were
used to investigate the relationships between parameters. The nonpara-
metricMann-Whitney test was used to compare groups ofmacaques, and
the nonparametric Wilcoxon signed-rank test was used to compare data
from the samemacaques at different time points, before and afterHAART
treatment. The nonparametric Kruskal-Wallis test, followed by Dunn’s
test, was used to compare viral loads, drug concentrations, and reference
gene expression levels between different tissues or body fluids. The Fisher
exact test was used to compare the percentages of SIV-positive animals in
the untreated and treated groups.P values of 0.05 or less in two-tailed tests
were considered significant.
RESULTS
SIV RNA persists in the semen of a subset of animals despite a
rapid decrease of viremia followingHAART.The chronically in-
fected animals (n 14) included in the study displayed a plasma
viral load (PVL) of between 4 and 5.5 log10 copies/ml (11,866 to
263,027 copies/ml) in the absence of treatment (median of 54,954
copies/ml for the untreated group and 70,958 for the treated
group before HAART) (Fig. 1A). The treated group was subjected
to TFV (PMPA)/FTC/LPV/RTV for 4 months, with intensifica-
tion with RAL over the last 7 weeks. RAL intensification was de-
signed to study its impact on persistent seminal shedding, as this
drug was reported to (i) have good penetration in semen in hu-
mans (70), (ii) rapidly decrease viral load in semen as well as HIV
FIG 1 Impact of treatment on viral load and viral dynamics in the blood. (A) Comparison of blood viral loads in untreated (n 8) and treated (n 6)macaques
before and at the end of treatment; (B) longitudinal follow-up of blood viral loads in treated animals (n  6) before and over the course of antiretroviral
treatment. Vertical lines indicate the initiation of therapy (HAART) and of intensification (iHAART). Each symbol represents one macaque. Statistical analysis
with nonparametric test: Mann-Whitney test (untreated versus treated) and Wilcoxon signed-rank test (treated before HAART versus treated at euthanasia).
Dotted lines represent the detection limit of the assay for vRNA (12 copies/ml). The gray areas delineate plasma viral loads of100 copies/ml.
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residual replication (14, 62, 63), and (iii) be effective against
SIVmac (64). The initiation of HAART quickly and drastically
decreased viremia. All the treated animals went down to a PVL
measurement of100 copies/ml at weeks 3 to 8 after the initiation
of HAART (threshold indicative of efficient HAART [52, 65–69],
delineated in gray on the graph in Fig. 1B). For 5 out of 6 animals,
the PVL remained under this threshold with only occasional blips
until euthanasia at week 17, going down to below the detection
limit of 12 copies/ml in several measurements for 4 animals. One
animal (OBCA5) presented a rebound of viremia at week 10. This
rebound was neither associated with a lower intake of oral LPV/
RTV nor with a lower concentration of antiretrovirals (ARVs) in
plasma (see Fig. S2 in the supplemental material). The viremia of
this animal declined after RAL intensification (Fig. 1B), to reach
184 copies/ml at euthanasia. At the end of the treatment, the me-
dian PVL of macaques subjected to HAART was 67 copies/ml
(Fig. 1A).
The median seminal viral loads (SVL) of the treated animals
before HAART and of the untreated animals were similar (respec-
tively, 3.3 log10 and 2.8 log10 copies/ml, i.e., 2,056 and 575 copies/
ml, P 0.47), whereas SVL significantly decreased after HAART
to a median below the limit of detection of the assay (	12 copies/
ml) (P 0.011) (Fig. 2A). For half of the animals, 2 to 4 weeks of
HAART was sufficient to achieve and maintain an undetectable
SVL throughout the treatment, even when high SVL were mea-
sured before treatment (Fig. 2B). However, viral sheddingwas still
observed during HAART in the semen of 3 animals displaying
PVL below 12 copies/ml in several measurements. In animal
30235, continuous SIV shedding was observed during the nonin-
tensified treatment period but decreased to undetectable levels
during intensification with raltegravir (Fig. 2B). Animal OKU6
displayed intermittent seminal shedding and OBCY5 rebounded.
For these twomacaques, the SVLmeasured at the end of treatment
was discordant with PVL and in the same range as that before
treatment (Fig. 2A and B).
HAART has no impact on SIV DNA in MGT organs.We de-
veloped a highly sensitive two-step quantitative PCR capable of
detecting SIV nucleic acids in tissues with low levels of infection,
as described in Materials and Methods. To assess the efficiency of
HAART in reducing infection at the tissue level, SIVDNAwas first
measured by quantitative PCR in axillary lymph node biopsy
specimens collected in the treated group of animals before and at
the end of the HAART treatment. In all the animals tested, a dras-
tic decrease of axillary lymph node viral DNA (vDNA) level was
observed after HAART (Fig. 3A). Using the two-step quantitative
PCR, we similarly found significantly lower levels of vDNA in the
spleens from treated than from untreated animals, further con-
firming HAART efficiency within deep tissues (Fig. 3B). In con-
trast, HAART had no significant impact on the median vDNA
levels in the testes, epididymides, seminal vesicles, prostates, vas
deferens, and urethras of treated compared to untreated animals
(Fig. 3C). However, two treated animals consistently tested nega-
tive for SIV DNA in the prostate and one animal in the vas defer-
ens, whereas all untreated animals tested positive in these tissues
(Fig. 3C; see Table S1 in the supplemental material). Regarding
vDNA in semen, seminal cells from all treated and untreated ani-
mals were positive in PCR (see Table S1).
HAART significantly decreases SIV RNA in several MGT or-
gans but has no significant impact in the urethra.We used two-
step quantitative PCR tomeasure viral RNA (vRNA) in the spleen
and in theMGTorgans, in the presence (n 6) or absence (n 8)
of HAART. In the spleen, HAART drastically reduced the median
vRNA level by 4.2 log10 (P 0.0007) (Fig. 4A). In the MGT from
untreated animals, vRNA levels in the epididymides, seminal ves-
icles, prostates, and vas deferens were within the same range (Fig.
4B). The testis was among the least productively infected MGT
organ, as we previously described (45), whereas the urethra was
among the most infected (Fig. 4B). HAART significantly reduced
vRNA in the epididymis, seminal vesicle, prostate, and vas defer-
ens by, respectively, 1.4, 1.9, 5, and 4.8 log10 (Fig. 4B). The most
profound effect was found in the prostate and vas deferens, with
median levels after HAART below the detection threshold (Fig.
4B) and only 33% of animals testing positive for SIV RNA after
HAART, as opposed to 100% without HAART (P  0.015) (see
Table S1). Although HAART decreased SIV RNA in the testis to a
very lowmedian level, it did not reach significance (P 0.08) (Fig.
FIG 2 Impact of treatment on viral load and viral dynamics in semen. (A) Comparison of semen viral loads in untreated (n 6) and treated (n 6) macaques
before and at the end of treatment; (B) longitudinal follow-up of semen viral loads in treated animals (n  6) before and over the course of antiretroviral
treatment. Vertical lines indicate the initiation of therapy (HAART) and of intensification (iHAART). Each symbol represents one macaque. Statistical analysis
with nonparametric test: Mann-Whitney test (untreated versus treated) and Wilcoxon signed-rank test (treated before HAART versus treated at euthanasia).
Dotted lines represent the detection limit of the assay for vRNA (12 copies/ml).
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4B). HAART had no significant impact on vRNA level in the ure-
thra (P  0.12) when comparing the 6 untreated and 4 treated
animals for which this tissuewas available (Fig. 4B). Of note is that
when the other MGT organs from the same animals were com-
pared, vRNA levels were still significantly decreased in the prostate
(P  0.013), vas deferens (P  0.018), and seminal vesicle (P 
0.04) and became borderline for the epididymis (P  0.05). The
decrease remained nonsignificant in the testis (P 0.087).
In situ hybridization experiments demonstrated the presence
of SIV RNA cells in the lamina propria of the urethra of both
treated and untreated animals (n  3 tested in each group), in-
cluding animal 23014 with viremia consistently below 12 cop-
ies/ml (Fig. 5C and D). Further comparative quantification could
not be undertaken due to the small tissue surface area of the ure-
thra (the macaque’s penile urethra being a small duct) and the
rarity of material available. Furthermore, the patchy distribution
of the infected cells was another additional intrinsic obstacle to
quantification. In contrast to the urethra, we failed to detect SIV
RNA cells in the testis, epididymis, prostate, and seminal vesicles
following HAART despite extensive screening of the animals test-
ing positive in RT-PCR for SIV RNA (minimum of 30 sections/
organ/animal) and even though larger tissue surface areas than
that of urethral ducts were screened, whereas these organs dis-
played infected cells in the absence of HAART (as shown for pros-
tate in Fig. 5F), in agreement with our published findings (45, 54).
The very low level of vRNA observed through quantitative RT-
PCR in these organs after treatment, together with the scattered
distribution of infected cells in therapy-naive animals, is likely to
account for the lack of detection using in situ hybridization.
Antiretroviral drug concentrations in semen, testis, epididy-
mis, prostate, and seminal vesicle do not correlate with viral
shedding in semen. Since suboptimal antiretroviral concentra-
tions in semen and/or in someMGT tissuesmay be responsible for
persistent viral production and seminal shedding, we investigated
the concentrations of the antiretroviral drugs in semen and four
MGT organs using validated ultrahigh-performance liquid chro-
matography (ultra-HPLC) with mass spectrometry detection.
Prior to this, the drug pharmacokinetics and concentrations in the
blood of the treated macaques were assessed at different time
points, in order to confirm the good systemic levels of the drugs
(see Fig. S2 in the supplemental material). In semen, concentra-
tions of all the antiretrovirals measured 24 h after drug adminis-
tration (C24h) were in the same range as those measured in HIV-
1-infected patients under suppressive HAART (70–74) and, as
described in other body fluids (75, 76), were well above C24h in
blood, suggesting better stability (Fig. 6A andB). Interestingly, the
highest drug concentrations in semen were measured for a persis-
tent shedder (OBCY5) (Fig. 6B), indicating that seminal shedding
FIG 3 Impact of treatment on SIV DNA levels in lymphoid and MGT tissues. (A) Axillary lymph node biopsy specimens were collected from treated animals
before and after 4 months of HAART for SIV DNA quantification. SIV DNA was measured in the spleen (B) and MGT tissues (C) from treated and untreated
animals, using a two-step quantitative PCR. Each symbol in the graph represents the mean from two tissue fragments from one animal. Dotted lines represent
the detection limit of the SIV DNA quantitative assay. Statistical analysis with a Mann-Whitney nonparametric test.
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despite HAART in this animal was not due to lower drug concen-
trations in semen than in nonshedders. No correlation was found
between vRNA levels and individual drug concentrations in se-
men at the end of HAART (P 0.33, Spearman test; see Table S2
in the supplementalmaterial). This is similar towhatwas observed
in men receiving HAART (73, 77).
We thenmeasured drug concentrations inMGT tissues (TFV-
DP, FTC-TP, LPV, RTV, RAL) to determine whether they corre-
lated with seminal shedding and whether differences in drug pen-
etration may explain the differential effect of HAART on MGT
tissue infection. We found that the median concentrations of the
active phosphorylated form of reverse transcriptase inhibitors
(TFV-DP and FTC-TP) were the lowest in the testis and epididy-
mis and the highest in the prostate and seminal vesicles (Fig. 6C).
LPV and RAL concentrations were the lowest in testis (Fig. 6C).
For all inhibitors, the prostatewas the organ forwhich themost
heterogeneous drug levels were observed among animals (Fig.
6C). However, there was no significant difference among MGT
organs for any drug concentration (Kruskal-Wallis–Dunn’s test).
The small size of the excurrent ducts (i.e., vas deferens and ure-
thra) precluded pharmacological measurements. Importantly, no
correlations were observed between drug concentrations in epi-
didymis, testis, and prostate and their tissue vRNAor vDNA levels
at the end of 4 months of HAART (Spearman test; see Table S2 in
the supplementalmaterial for vRNA). Statistically significant neg-
ative correlations between antiretroviral concentrations and tis-
sue SIV RNA level were found only for ritonavir in the seminal
vesicles (P 0.033, Spearman r0.89; see Table S2). No neg-
ative correlations were found between the level of ARVsmeasured
in MGT organs and SIV RNA loads in semen (Spearman test; see
Table S3 in the supplemental material).
Nature and quantification of SIV target cells in MGT organs
with and without HAART. We investigated SIV potential target
cells in 3 MGT organs (urethra, epididymis, and prostate) in
which HAART had a different effect on SIV RNA levels. The ure-
thra clearly showed numerous macrophages as identified using a
combination of antibodies against CD68 and CD163, located in
the lamina propria and to a lesser extent in the epithelium (Fig.
7A). CD4 T lymphocytes were 3- to 6-fold less numerous than
macrophages (Fig. 7A) and represented on average 39% of CD3
cells in the urethra (see Fig. S3 in the supplemental material).
Similar numbers of macrophages and CD4 T lymphocytes were
FIG 4 Impact of treatment on SIV RNA levels in spleen and MGT tissues. SIV RNA was measured in the spleen (A) and MGT tissues (B) from treated and
untreated animals using a two-step quantitative RT-PCR. Each symbol in the graph represents themean from two tissue fragments fromone animal. Dotted lines
represent the detection limit of the SIV RNA quantitative assay. Statistical analysis with a Mann-Whitney nonparametric test.
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found in the urethral tissue from treated and untreated animals
(Fig. 7A). In the epididymis, scattered tissuemacrophages, located
in both stroma and epithelium, were 30- to 60-fold more abun-
dant than CD4 T lymphocytes (Fig. 7A), which represented on
average 60%of CD3T lymphocytes (see Fig. S3). In the prostate,
similar numbers of macrophages and CD4 T lymphocytes (50%
of CD3 T lymphocytes [see Fig. S3]) were observed (Fig. 7A).
These numbers were unchanged byHAART (Fig. 7A). In addition
to these scattered leukocytes and as we previously described (45,
54), HLA-DR immune cell infiltrates composed of potential SIV
target cells (i.e., CD4 T lymphocytes and CD68myeloid cells)
and other immune cell types (cytotoxic T lymphocytes andB cells)
were observed in the epididymis, prostate, and seminal vesicle
from infected macaques (see Fig. S4 in the supplemental mate-
rial). Such cell foci were absent from the urethra and testis, where
isolated HLA-DR cells were more homogenously distributed
and barely present, respectively (see Fig. S4). To take into account
the heterogeneous distribution and size of the infiltrates, the large
surface areas of the epididymis and prostate were screened for
semiquantitative analysis of HLA-DR cell foci. A lower number
FIG 5 Detection and localization of SIV-infected cells in theMGT tissues by in situ hybridization. (A) Positive control, sections of mesenteric lymph node from
an untreated animal hybridized with SIV antisense probe showing infected cells (arrows); (B) negative control, parallel sections of mesenteric lymph node
hybridized with SIV sense probe showing no signal; urethra from untreated (C) and treated (D) macaques displaying infected cells (arrows); (E) hybridization
of parallel sections of urethra with SIV sense probe showing no signal for SIV RNA (negative control); (F) prostate from untreated macaque displaying infected
cells (arrows). Scale bar 50 m.
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of immune cell infiltrates, and thus a reduced number of potential
SIV target cells, was observed in treated animals than in untreated
animals, indicating lower local inflammation (Fig. 7B). Overall,
the urethras from treated and untreated animals consistently dis-
played a much higher proportion of SIV target cells than the epi-
didymides and prostates, even when considering immune cell in-
filtrates in the latter.
SIV RNA macrophages are detected in the urethra post-
HAART. We analyzed the nature of SIV RNA cells in the MGT
tissues using in situ hybridization for SIVRNA combinedwith cell
markers. In agreement with our published findings (45, 54), we
evidenced the presence of infected T lymphocytes and macro-
phages in MGT organs from therapy-naive animals (as shown for
prostate in Fig. 8G). In contrast to untreated animals, infected
CD3 T lymphocytes were never encountered in MGT organs
after treatment. However, we revealed the presence of SIV RNA
within CD68/CD163 macrophages localized in the lamina pro-
pria of the urethra from treated animals, including animal 23014
with suppressed viremia (Fig. 8C, E, and F).
DISCUSSION
A growing number of studies are reporting the persistence of HIV
RNA and DNA in the semen of a subset of HIV-infected men
receiving suppressiveHAART in the blood for an extended period
of time (reviewed in reference 20). This persistent shedding is
believed to arise from local sources within the MGT, but the na-
ture of these sources remains unknown. With the resurgence of
theHIV-1 epidemic in countries whereHAART iswidely available
(38), understanding the origin and causes of this viral shedding is
an essential step on the path to better treatment. To this end, this
study provides the first analysis of semen and awide range ofMGT
tissues (testis, epididymis, seminal vesicle, prostate, vas deferens,
and urethra) in macaques treated by HAART. SIV RNA and DNA
were quantified in semen and MGT tissues and drug concentra-
tions measured. In addition, the nature and impact of the treat-
ment on SIV target cells in male reproductive tissues were ana-
lyzed.
Our results reveal that although HAART can lead to undetect-
able viral load in macaque semen, seminal SIV shedding occurs in
a subset of animals despite drastically reduced viremia in the
blood, as is seen in humans (reviewed in reference 20). Where the
macaque model offers a unique advantage over human patient
studies is that it avoids the effects of medication nonadherence
and acquisition of other STIs during the course of HAART, which
are known to increase HIV release in semen (10, 80). We showed
that shedding in semen during HAART is not linked to reduced
ARV concentrations in semen. This corroborates the observation
of persistent HIV shedding in the semen of men receiving drugs
usually achieving good concentrations in semen (6, 9, 17, 18). The
intensification of HAART with raltegravir over the last 7 weeks of
FIG 6 Concentrations of antiretroviral drugs in blood, semen, and MGT tissues. Blood plasma (A) and seminal plasma (B) concentrations of emtricitabine
(FTC), tenofovir (TFV), lopinavir (LPV), ritonavir (RTV), and raltegravir (RAL) measured 24 h postadministration (C24h) 120 days post-HAART at the time
of euthanasia. (C) MGT tissue concentrations (ng/g) of emtricitabine-triphosphate (FTC-TP), tenofovir-diphosphate (TFV-DP), lopinavir (LPV), ritonavir
(RTV), and raltegravir (RAL) in the MGT tissues (T, testis; E, epididymis; P, prostate; SV, seminal vesicles). Each symbol in the graphs represents one macaque.
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treatment was tested in macaques, as it was reported to induce a
rapid decrease of semen viral load compared with that of standard
HAART in men (14). Whereas raltegravir had no impact on sem-
inal SIV load in the two animals displaying intermittent shedding,
SIVwas no longer detected at the end of intensifiedHAART in the
semen of a continuous persistent shedder. Although it cannot be
ruled out that the decrease in the semen SIV load of this animal
was simply following its natural course, differences in seminal
virus sources (i.e., systemic compartment versus MGT) among
animals may explain the differential effect of intensification, and
more generally of ARVs, on semen viral load. Thus, an intermit-
tent shedding pattern (as observed in the two persistent shedders)
has been associated in therapy-naive individuals with the presence
of viral strains in semen distinct from those in blood, indicative of
local production. In contrast, seminal strains similar to blood
strains were observed in patients with continuous shedding of
HIV in semen (81). Prolonged shedding in semen during potent
HAART is frequently intermittent (6, 16–18, 78, 79), with seminal
viral strains reported to be distinct from blood strains (6). We
postulate that the resistance to treatment observed in the two in-
termittent shedders compared with the continuous shedder may
reflect local compared to systemic origin of the seminal virus.
Phylogenetic analysis of seminal and blood viral strains would be
required to substantiate this assumption butwas beyond the scope
of this study.
Semen is composed of cells and secretions originating from
the MGT, which itself comprises several exocrine organs
(namely the testes, the epididymides, the seminal vesicles, the
prostate, and the bulbourethral glands) and ducts (the efferent
duct, the vas deferens, the ejaculatory ducts, and the urethra).
We performed a thorough investigation into the infection of
the MGT organs and ducts from treated and untreated animals
and found a differential effect of HAART depending on the
tissues. HAART led to undetectable median levels of vRNA in
the prostate and vas deferens and significantly decreased vRNA
levels in the epididymis and seminal vesicle. The testis infection
level was extremely low after HAART. Using in situ hybridiza-
tion, infected cells could not be detected in those tissues despite
FIG 7 Quantification of SIV target cells and immune cell foci in the MGT tissues. (A) Quantitative analysis of the number of scattered macrophages (identified
using a combination of antibodies against CD68 andCD163) and CD4T lymphocytes in the urethra, epididymis, and prostate from untreated (white bars) and
treated (red bars) animals (n 3 in each group). (B) Semiquantitative analysis of the number of HLA-DR immune cell foci in epididymis and prostate from
untreated (white bars, n  8) and HAART-treated (red bars, n  6) macaques. Cell foci were divided into three categories based on the number of cells they
encompassed: small foci (between 15 and 49 HLA-DR cells), medium foci (between 50 and 200 cells), and large foci (over 200 cells). Numbers of cells in each
focus category are indicated on the x axis. Histograms represent the means 
 standard errors of the mean (SEM) of the number of cell foci in each category.
Statistical analysis with a Mann-Whitney nonparametric test.
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extensive screening. In contrast, in the urethra, we did not
observe any significant difference in vRNA level and infected
cells were still readily detected after HAART.
One limitation to our study is the relatively short course of
HAART (17 weeks) compared to the human treatment and the
fact that viremia was not fully suppressed (i.e., below 12 copies/
ml) at all time points in the animals, except for one macaque
(23014). Thus, seeding ofMGT organs from the periphery during
the HAART treatment cannot be completely ruled out. Of note,
however, is the fact that animal 23014 with consistently sup-
pressed viremia had vRNA levels in MGT organs similar to those
of other animals and infected macrophages were detected in the
urethra.
Low drug penetration has been shown in tissues displaying
residual productive infection in the face of HAART, such as lym-
phatic organs and brain (60, 82, 83). Due to the poor accessibility
to the male genital organs, ARVs have never been assayed in male
genital tissues. Similar ARV concentrations were found among all
the MGT organs tested. Unfortunately, because of its small size
and the fact that other experiments had to be performed, drug
levels in the urethra could not be measured. Slightly lower drug
levels were generally measured in the testis, as expected due to the
presence of numerous drug efflux pumps and of the blood-testis
barrier (84–86). The testis has been postulated as being able to
constitute a viral sanctuarywithin theMGT (reviewed in reference
86). However, the very low level of infection of this organ follow-
ing HAART, together with the localization of infected cells in the
interstitium distant from the seminal lumen (reported by us and
others [45, 47]), argues against the testis being an important con-
tributor to virus in semen during HAART. It can be assumed that
ARV concentrations in the MGT organs analyzed were sufficient
to control viral replication, since SIV RNA levels and SIV RNA
cell detection were impacted by HAART. Whether this control
eventually leads to full viral suppression remains to be determined
through longer time course experiments. Animals persistently
shedding SIV in semen, compared to nonshedders, did not display
significantly different drug concentrations in the MGT tissues
tested, indicating that the release of virus in semen duringHAART
is not associated with suboptimal drug concentrations in these
organs (i.e., testis, epididymis, prostate, and seminal vesicle).
The urethra displayed a high number of SIV target cells (pri-
marilymacrophages) in both treated and untreatedmacaques and
was generally the organ displaying the highest level of viral RNA
within the MGT. Such a high number of macrophages was also
reported for the urethra from healthy uninfected men (87–89).
The majority of T lymphocytes in macaques’ urethras were CD4
FIG 8 Phenotyping of SIV RNA cells in the MGT tissues by combined im-
munofluorescence and in situ hybridization. Quadruple label fluorescencemi-
croscopy to identify macrophages (CD68/CD163, red), T lymphocytes (CD3,
white), and SIV RNA expression (ISH, green). Cell nuclei are stained by DAPI
(blue). (A) Positive control, tissue sections hybridized with antisense probe
showing infected T lymphocytes (arrows) in the seminal vesicle from a highly
(acutely) infected animal; (B) negative control, parallel tissue sections of sem-
inal vesicle hybridized with SIV sense probe showing no signal for SIV RNA;
(C, E, F) urethra from treated macaques displaying SIV RNA macrophages
(arrowheads); (D) negative control, hybridization of parallel sections of ure-
thrawith SIV sense probe showing no specific signal for SIVRNA; (G) prostate
from untreated chronic macaque displaying infected T lymphocyte (arrow).
Large panels represent merged images combining all channels. Side panels
represent individual channels. Scale bar 20 m.
Matusali et al.
5782 jvi.asm.org June 2015 Volume 89 Number 11Journal of Virology
negative, as previously reported for human urethral tissue (87,
88). We evidenced the presence of SIV RNAmacrophages in the
urethra from HAART-treated macaques with reduced or unde-
tectable viremia. In agreement with our findings in macaques in
vivo, the preferential infection of resident macrophages was re-
cently described in human urethral tissue exposed ex vivo to
HIV-1 (87). It was recently suggested that myeloid cells in the gut
and lymphoid tissues from SIV-infected primates are resistant to
infection and acquire SIVDNA primarily through the phagocyto-
sis of infected T cells (90). However, it was reported that macro-
phages in lymph nodes andmucosal tissues get heavily infected in
macaques depleted in CD4 T cells (91) and that the uptake of
HIV-infected T lymphocytes by blood-derivedmacrophages leads
to their infection (92). Macrophages are functionally and pheno-
typically extremely heterogeneous among anatomical sites. For
instance, whereas intestinal macrophages have been shown to be
resistant to HIV infection, vaginal macrophages are permissive
(93). Infectedmyeloid cells in the brain are also widely believed to
play an important role in neurocognitive disorders. Although we
cannot be sure that SIV RNA detection in urethral macrophages
reflects their productive infection, the fact that we did not evi-
dence SIV RNA T lymphocytes in the urethra argues against
phagocytosis of infected CD4 T cells as the main mode of SIV
RNA acquisition in those macrophages. Tissue-resident macro-
phages have the potential to constitute long-term viral reservoirs.
In addition to being much more resistant to cytopathic effects of
lentiviral replication than activated T cells, tissue macrophages
can live from several weeks up to years (94) and have been shown
capable of self-renewal (95). Therefore, long-lived, and possibly
self-renewing, urethralmacrophagesmay be able to produce virus
for extended time periods. To determinewhether the urethra con-
stitutes an as-yet-unrecognized anatomical reservoir for HIV, an
investigation into urethra infection in infected men with pro-
longed suppressed viremia under HAART would be required. In
addition, measurement of ARV concentrations in this organ
would be easier performed in men than macaques due to the big-
ger size of this organ.
The relatively high level of infection of the urethra evidenced in
our study compared to infection of other MGT organs suggests
that the urethramay play a substantial role in the seeding of semen
with infected leukocytes and virions. Indeed, several studies in
therapy-naivemen support such a role: urethral swabswere found
to contain significant amounts of HIV RNA (96), and HIV RNA
and DNA were detected in the preejaculatory fluid coming from
the urethra (97, 98). Phylogenetic analysis would be needed to
demonstrate that the urethra is indeed a source of virus in semen
during HAART. However, the relatively low semen viral load in
treated animals, together with the very limited semen volume ex-
tractable from macaques (maximum of 500 l/ejaculate), repre-
sents a major obstacle against obtaining sufficient seminal viral
amplicons for reliable phylogenetic analysis (42, 99). As an alter-
native, phylogenetic comparison of viral strains in the semen,
MGT organs, and blood from therapy-naive animals with com-
partmentalized seminal strains and high SVLwould help establish
the role of the urethra and other MGT organs in semen contami-
nation.
We previously demonstrated in both men and therapy-naive
macaques the infection of T lymphocytes andmacrophages in the
epididymis, prostate, seminal vesicles, and testis using in situ hy-
bridization combined with immunostaining (43, 45, 47, 54, 100).
Infected T lymphocytes predominated in the prostate (100),
whereas infected macrophages were encountered primarily in the
epididymis, seminal vesicle, and testis, together with some in-
fected T lymphocytes (43, 45, 47). Such infected cells were no
longer detected in these organs after 4 months of HAART in ma-
caques. Productively infected T lymphocytes are short-lived, and
their eradication during HAART inMGT tissues further indicates
that antiretroviral drug concentrations in theMGT are efficient. A
substantial proportion of infected macrophages in the MGT of
therapy-naive animals may be short-lived infiltrating macro-
phages cleared during HAART. The much lower proportion of
residentmacrophages inMGTorgans other than the urethramost
likely explains the failure to detect infected macrophages after
HAART in these tissues. We hypothesize that the residual level of
SIV RNA detected in the epididymis, seminal vesicle, and testis
afterHAART is due to infected residentmacrophages, too scarcely
distributed to be detected on tissue slides. Alternatively, seeding of
genital tract organs by ongoing viral replication in the periphery
may be involved in the low levels of residual vRNA observed in
those organs, as the duration of HAART (17 weeks) was relatively
short and the macaques’ viremia levels were not consistently be-
low 12 copies/ml, except for one animal. Activated immune cell
infiltrates encompassing SIV target cells were encountered in the
epididymis, prostate, and seminal vesicles of untreated animals, in
agreement with previous findings of our team and others in in-
fected men and macaques (45, 101, 102). We previously showed
that infection level was a crucial determinant of leukocyte recruit-
ment in these tissues, as leukocyte infiltrates were absent in unin-
fected animals and in animals with low viremia and low MGT
tissue infection (45). The number of inflammatory infiltrates was
significantly reduced in the prostate and to a lesser extent in the
epididymis of treated animals, in line with their decreased level of
SIV RNA. Immune cell foci were never observed in the testis,
which may be due to its naturally immunosuppressive environ-
ment. As for urethra, although cell foci were not observed, we
cannot rule out an increase in immune cells caused by the infec-
tion.
We showed that the course of HAART performed in this study
had nomajor impact on the detection of vDNA inMGT tissues in
which vRNA levels were drastically decreased, reflecting the pref-
erential removal of productively infected cells. In line with our
findings, the persistence of vDNA in the absence of vRNA detec-
tion was found in the testis, prostate, and seminal vesicles from
juvenile rhesus macaques infected with reverse transcriptase sim-
ian-human immunodeficiency virus (SHIV) treated by HAART
for 26weeks (52). A similar differential effect ofHAARTon vDNA
and vRNA levels has been reported in the brain, a well-established
HIV/SIV reservoir (67). The lack of HAART impact on vDNA
suggests the presence of long-lived cells containing very low vRNA
copies, such as latently infected memory T cells (which may be
reactivated over time to produce virus and prevent full eradication
in the MGT), macrophages producing low level of SIV RNA, or
cells harboring defective vDNA. The detection of SIV DNA in
MGT tissues was paralleled with the detection of SIV DNA in
seminal cells from treated animals. Determining whether this de-
tection results from tissue-resident cells or migration into the
MGT of peripheral cells encompassing vDNA requires phyloge-
netic analyses of vDNA in blood and MGT tissues. We recently
showed that both CD4 T lymphocytes andmacrophages present
in the semen of therapy-naive macaques contain SIV DNA and
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can produce virus (29). In men under suppressive HAART, the
presence of replication-competent virus has been shown in semi-
nal leukocytes for up to 3 years after treatment initiation (7, 10,
23–26, 103, 104). On the basis of the present results and of our
previous demonstration of the infection of female macaques fol-
lowing vaginal exposure to infected cells (28), a future study into
the ability of persistently infected seminal cells to transmit infec-
tion in a sexual partner in macaques is of strong interest.
In conclusion, we showed that SIV shedding occurs in the se-
men ofmacaques despite a course ofHAART leading to drastically
decreased viremia. This shedding is not linked to lower drug con-
centrations in semen, testis, epididymis, seminal vesicle, or pros-
tate. Drug concentrations in the urethra remain to be tested. The
effect ofHAARTwas variable among theMGTorgans. Our results
suggest that seminal shedding during HAART could result from
the production of virus by long-lived cells within the MGT, such
as the infectedmacrophages detected within the urethra of treated
animals. Long-term HAART leading to fully suppressed viremia
and phylogenetic analyses are required to fully substantiate this
assumption.Our results pave theway for future studies into (i) the
male genital organs and especially the urethra as a source ofHIV in
semen, through phylogenetic comparison of strains in semen and
genital organs, (ii) the kinetics of virus decay in the male genital
tract through the longer follow-up of animals receiving HAART,
(iii) the infectiousness of the remaining free virus and infected
cells in semen, and (iv) the factors triggering seminal shedding
from the persistently infected genital organs during HAART.
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